Blood Research最新文献_第3页

Pathologic characteristics of histiocytic and dendritic cell neoplasms. 组织细胞和树突状细胞肿瘤的病理特征。

IF 2.2

Blood Research Pub Date : 2024-05-07 DOI: 10.1007/s44313-024-00015-9

Sun Och Yoon

{"title":"Pathologic characteristics of histiocytic and dendritic cell neoplasms.","authors":"Sun Och Yoon","doi":"10.1007/s44313-024-00015-9","DOIUrl":"10.1007/s44313-024-00015-9","url":null,"abstract":"Histiocytic and dendritic cell neoplasms comprise diverse tumors originating from the mononuclear phagocytic system, which includes monocytes, macrophages, and dendritic cells. The 5th edition of the World Health Organization (WHO) classification updating the categorization of these tumors, reflecting a deeper understanding of their pathogenesis.In this updated classification system, tumors are categorized as Langerhans cell and other dendritic cell neoplasms, histiocyte/macrophage neoplasms, and plasmacytoid dendritic cell neoplasms. Follicular dendritic cell neoplasms are classified as mesenchymal dendritic cell neoplasms within the stroma-derived neoplasms of lymphoid tissues.Each subtype of histiocytic and dendritic cell neoplasms exhibits distinct morphological characteristics. They also show a characteristic immunophenotypic profile marked by various markers such as CD1a, CD207/langerin, S100, CD68, CD163, CD4, CD123, CD21, CD23, CD35, and ALK, and hematolymphoid markers such as CD45 and CD43. In situ hybridization for EBV-encoded small RNA (EBER) identifies a particular subtype. Immunoprofiling plays a critical role in determining the cell of origin and identifying the specific subtype of tumors. There are frequent genomic alterations in these neoplasms, especially in the mitogen-activated protein kinase pathway, including BRAF (notably BRAF V600E), MAP2K1, KRAS, and NRAS mutations, and ALK gene translocation.This review aims to offer a comprehensive and updated overview of histiocytic and dendritic cell neoplasms, focusing on their ontogeny, morphological aspects, immunophenotypic profiles, and molecular genetics. This comprehensive approach is essential for accurately differentiating and classifying neoplasms according to the updated WHO classification.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"18"},"PeriodicalIF":2.2,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare pseudo-chediak-higashi inclusions in a patient with disseminated diffuse large B cell lymphoma. 一名播散性弥漫大B细胞淋巴瘤患者体内的罕见假性切迪克-东包涵体。

IF 2.2

Blood Research Pub Date : 2024-03-25 DOI: 10.1007/s44313-024-00013-x

Can Yan, Zenghui Fang, Jinlin Liu

引用次数: 0

Gaucher or pseudo-Gaucher cells. 戈谢细胞或假性戈谢细胞

IF 2.2

Blood Research Pub Date : 2024-02-28 DOI: 10.1007/s44313-024-00005-x

Gurpreet Kaur, Ankur Ahuja, Ganesh Kumar Vishwananthan, Arijit Sen

引用次数: 0

Comparable outcomes with low-dose and standard-dose horse anti-thymocyte globulin in the treatment of severe aplastic anemia. 低剂量和标准剂量马抗胸腺细胞球蛋白治疗重型再生障碍性贫血的疗效相当。

IF 2.2

Blood Research Pub Date : 2024-02-26 DOI: 10.1007/s44313-024-00003-z

Arihant Jain, Aditya Jandial, Thenmozhi Mani, Kamal Kishore, Charanpreet Singh, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Reena Das, Neelam Varma, Subhash Varma, Pankaj Malhotra

{"title":"Comparable outcomes with low-dose and standard-dose horse anti-thymocyte globulin in the treatment of severe aplastic anemia.","authors":"Arihant Jain, Aditya Jandial, Thenmozhi Mani, Kamal Kishore, Charanpreet Singh, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Reena Das, Neelam Varma, Subhash Varma, Pankaj Malhotra","doi":"10.1007/s44313-024-00003-z","DOIUrl":"10.1007/s44313-024-00003-z","url":null,"abstract":"Background: The standard dose (SD) of horse anti-thymocyte globulin (hATG) ATGAM (Pfizer, USA) or its biosimilar thymogam (Bharat Serum, India) for the treatment of Aplastic Anemia (AA) is 40 mg/kg/day for 4 days in combination with cyclosporine. Data on the impact of hATG dose on long-term outcomes are limited. Here, we describe our comparative experience using 25 mg/kg/day (low-dose [LD]) hATG for 4 days with SD for the treatment of AA.Methods: We retrospectively studied patients with AA (age > 12 years) who received two doses of hATG combined with cyclosporine. Among 93 AA patients who received hATG, 62 (66.7%) and 31 (33.3%) patients received LD and SD hATG with cyclosporine, respectively. Among these,seventeen(18.2%) patients also received eltrombopag with hATG and cyclosporine. Overall response rates [complete response (CR) and partial response (PR)] of LD and SD hATG groups at 3 months (50% vs. 48.4%; p = 0.88), 6 months (63.8% vs. 71.4%; p = 0.67), and 12 months (69.6% vs. 79.2%; p = 0.167) were comparable. The mean (Standard Deviation) 5-year Kaplan-Meier estimate of overall survival and event-free survival was 82.1 (4.6)% and 70.9 (5.5)% for the study population. The mean (standard deviation) 5-year Kaplan-Meier estimate of overall survival and event-free survival of those who received LD hATG versus SD hATG dose was 82.9 (5·3)% versus 74.8 (10·3)% (P = 0·439), and 75.2 (6.2)% versus 61.4(11.2)% (P = 0·441).Conclusion: Our study revealed that the response rates of patients with AA and LD were similar to those of patients with SD to hATG combined with cyclosporine in a real-world setting.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"6"},"PeriodicalIF":2.2,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10903521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral T-cell lymphoma, NOS in bone marrow and heart. 外周 T 细胞淋巴瘤，骨髓和心脏中的 NOS。

IF 2.2

Blood Research Pub Date : 2024-02-26 DOI: 10.1007/s44313-024-00009-7

Hye Won Lee, Ja Young Lee

引用次数: 0

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level. 在 NCCN-IPI 中加入 MYC/BCL2 双重表达可能无法将预后价值提高到可接受的水平。

IF 2.2

Blood Research Pub Date : 2024-02-19 DOI: 10.1007/s44313-024-00006-w

Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Chinnawut Suriyonplengsaeng, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee

{"title":"Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level.","authors":"Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Chinnawut Suriyonplengsaeng, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee","doi":"10.1007/s44313-024-00006-w","DOIUrl":"10.1007/s44313-024-00006-w","url":null,"abstract":"Background: MYC/BCL2 double expression (DE) is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). This study aimed to determine whether the addition of DE to the National Comprehensive Cancer Network Internal Prognostic Index (NCCN-IPI) could improve the prediction of disease progression in patients with DLBCL treated with R-CHOP.Methods: This confirmatory prognostic factor study retrospectively recruited patients with newly diagnosed DLBCL between January 1, 2014, and January 31, 2018, at Ramathibodi Hospital (RA) and Thammasat University Hospital (TU). The follow-up period ended on July 1, 2022. Tumors expressing MYC ≥ 40% and BCL2 ≥ 50% were classified as DE. We calculated the hazard ratios (HR) for progression-free survival (PFS) from the date of diagnosis to refractory disease, relapse, or death. Discrimination of the 5-year prediction was based on Cox models using Harrell's concordance index (c-index).Results: A total of 111 patients had DE (39%), NCCN-IPI (8%), and disease progression (46%). The NCCN-IPI adjusted HR of DE was 1.6 (95% confidence interval [CI]: 0.9-2.8; P = 0.117). The baseline NCCN-IPI c-index was 0.63. Adding DE to the NCCN-IPI slightly increased Harrell's concordance index (c-index) to 0.66 (P = 0.119).Conclusions: Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"59 1","pages":"2"},"PeriodicalIF":2.2,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10903517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia. 复发儿童急性髓系白血病的治疗结果和预后因素。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023152

Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo

{"title":"Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia.","authors":"Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo","doi":"10.5045/br.2023.2023152","DOIUrl":"10.5045/br.2023.2023152","url":null,"abstract":"Background: Despite improved outcomes for pediatric patients with acute myeloid leukemia (AML), the prognosis for relapse remains poor. This study aimed to examine the clinical factors associated with prognosis in relapsed pediatric AML.Methods: We conducted a chart review of pediatric patients with AML who experienced their first relapse and received treatment at our institution between 2008 and 2019. Risk stratification at diagnosis was performed according to the definition suggested by the ongoing AML 2012 study in Korea, and the clinical factors associated with prognosis were analyzed.Results: A total of 27 pediatric patients with relapsed AML were identified. The 5-year overall survival (OS) and event-free survival (EFS) rates were 32.9% and 32.9%, respectively. A duration ≥12 months from diagnosis to relapse had a favorable impact on survival outcomes (5-yr OS, 64.0% vs. 15.7%; P=0.007). Patients who achieved complete remission (CR) after 1 course of chemotherapy following relapse (N=15) had a 5-year OS rate of 59.3%, while none of the other patients survived (P＜0.0001). Additionally, the 5-year OS differed significantly based on the risk group at initial diagnosis (62.3% [favorable and intermediate prognosis groups, N=11] vs. 13.3% [poor prognosis group, N=15]; P=0.014).Conclusion: Patients with a longer duration of CR before relapse, who achieved CR following 1 course of reinduction chemotherapy, and were in the favorable or intermediate prognosis group at diagnosis demonstrated better outcomes. These findings emphasize the importance of tailoring treatment strategies based on the expected prognosis at relapse in pediatric patients with AML.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"181-186"},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TP53 mutation is a high-risk factor for Richter's syndrome based on circulating tumor DNA. 根据循环肿瘤DNA，TP53突变是里希特综合征的高危因素。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023189

Hee Sue Park, Bo Ra Son, Seung Myoung Son, Jihyun Kwon

引用次数: 0

Clinically relevant core genes for hematologic malignancies in clinical NGS panel testing. 临床NGS小组测试中血液系统恶性肿瘤的临床相关核心基因。

IF 2.3

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023196

Ju Sun Song

引用次数: 0

Incidental abdominal computed tomography findings in patients newly diagnosed with Philadelphia-negative myeloproliferative neoplasm. 新诊断为费城阴性骨髓增生性肿瘤的患者的偶然腹部计算机断层扫描结果。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-10-19 DOI: 10.5045/br.2023.2023049

Ik-Chan Song, Jeong Suk Koh, Sora Kang, Myung-Won Lee, Kyung Sook Shin, Deog-Yeon Jo

引用次数: 0